TRIPP, MATTHEW L,BABISH, JOHN G,BLAND, JEFFREY,HALL, AMY JENNAE,KONDA, VEERA,PACIORETTY, LINDA,DESAI, ANU
申请号：
NZ56886006
公开号：
NZ568860A
申请日:
2006.12.11
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is the use of a composition in the manufacture of a medicament for treating a disease or disorder responsive to modulation of the activity of a protein kinase in a subject in need thereof, wherein said composition comprises (i) a reduced isoalpha acid, and (ii) a component or extract derived from Acacia wherein a. said protein kinase is selected from the group consisting of ABL, AKT, AMPK, AURORA, BTK, CAMK, CDK, CHK, CSK, DBF2/20,EGFR, EPH/ELK/ECK, ERK/MAPKFGFR, GSK3, IGF-IR, IKKB, INSR, JAK DOM 1/2, MARK/PRKAA, MEK/STE7, MEKK/STE 11, MLK, mTOR, PAK/STE20, PDGFR, PI3K, PKC, POLO, SRC, TEC/ATK, and ZAP/SYK b. the reduced isoalpha acid is selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydroisoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydroisocohumulone, hexahydro-isoadhumulone, and rho-isoalpha acids and c. the component or extract derived from Acacia is derived from Acacia catechu or Acacia nilotica.
